Research article · 17 Jul 2026
Conference abstractPublished 8 Jun 2018
Navigating the Canadian drug establishment licensing system
Therapeutic Products Inc, Canada
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
An establishment license since January 1, 1998 must be holded by all Canadian drug establishments in all the processes from fabrication to testing a drug. This requirement applies to all drug establishments. It is not permit, except in accordance with an establishment license, to fabricate, package/label, distribute, import or wholesale a drug; or perform tests, including examinations, required under Part C Division 2 of the Canadian Food and Drugs Regulations. Part C, Division 2 also applies to foreign buildings that supply Canadian importers with Finished Drug Products (FP), Active Pharmaceutical Ingredients (API), (including any FP and API intermediates) for import into Canada or import into Canada for future export. US Market Authorization Holders (MAH) must ensure any US site to plan to use in support a drug submission are aligned with an importer of record and the Health Canada (HC) process for GMP Canadian GMP compliance.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Developing Drugs.
Commentary · 4 Feb 2026
Vaccine Development and Global Disease Prevention
Commentary · 4 Feb 2026
Transforming Drug Development Through Pharmaceutical Biotechnology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Doreen Clark Steen”
